<DOC>
	<DOCNO>NCT02442414</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose KBP-5209 single agent give orally adult patient advance solid tumor progress despite standard therapy , standard therapy .</brief_summary>
	<brief_title>A Phase 1 Study KBP-5209 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This Phase 1 , open-label , multicenter study KBP-5209 administer orally daily ( QD ) 28-day treatment cycle adult patient advance solid tumor progress despite standard therapy standard therapy exist . This study design determine MTD RP2D characterize safety , tolerability , PK profile KBP-5209 .</detailed_description>
	<criteria>Age 18 year old ; Patients histologically cytologically confirm , advance solid tumor progress despite standard therapy standard therapy exists . Patients must least one measurable nonmeasurable lesion ( dose escalation ) define RECIST v1.1 Eastern Cooperative Oncology Group performance score 0 2 ; Patients symptomatic CNS metastasis ; Patients know history hepatitis C chronic active hepatitis B know diagnosis HIV Any significant ophthalmologic abnormality Patients severe and/or uncontrolled medical condition Significant gastrointestinal abnormality , Patients impair cardiac function clinically significant cardiac disease , Chemotherapy , biologic therapy , immunotherapy , radiotherapy investigational agent within 5 halflives within 4 week ( whichever longer ) prior administration first dose study drug Day 1 recover side effect therapy ; Treatment third generation EGFR inhibitor Major surgery/surgical therapy cause within 4 week Screening ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>EGFR</keyword>
	<keyword>HER2</keyword>
	<keyword>HER3</keyword>
	<keyword>HER4</keyword>
	<keyword>ALK mutation</keyword>
	<keyword>irreversible tyrosine kinase inhibitor</keyword>
	<keyword>Metastatic Non Small Cell Lung Cancer</keyword>
	<keyword>Gastric Cancer</keyword>
	<keyword>Colorectal Cancer</keyword>
</DOC>